Novel molecular trends in the management of advanced non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 6, 2012, Pages 729-732

  Metro, Giulio ^a   Crinò, Lucio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

ALK; angiogenesis; bevacizumab; BRAF; crizotinib; KRAS; NSCLC; squamous cell carcinoma of the lung

Indexed keywords

AFLIBERCEPT; ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CRIZOTINIB; DABRAFENIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; NINTEDANIB; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SALIRASIB; SELUMETINIB; SORAFENIB; TIPIFARNIB; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANAPLASTIC LYMPHOMA KINASE GENE; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DIPLOPIA; DISCOIDIN DOMAIN RECEPTOR 2 GENE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EML4 GENE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT PLANNING; TREND STUDY; TUMOR GENE; VISUAL IMPAIRMENT; VITREOUS FLOATERS;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862899891     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.51     Document Type: Conference Paper

References (25)

1. Weiss J, Sos ML, Seidel D et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2(62), 62ra93 (2010).
2. Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 6(6), e20351 (2011).
3. Hammerman PS, Sos ML, Ramos AH et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1(1), 78-89 (2011).
4. Camidge DR, Bang Y, Kwak EL et al. Progression-free survival (PFS) from a Phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2501).
5. Crinò L, Kim D, Riely GJ et al. Initial Phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 7514).
6. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363(18), 1734-1739 (2010).
7. Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71(18), 6051-6060 (2011).
8. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18(5), 1472-1482 (2012).
9. Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4(120), 120ra17 (2012).
10. D'Addario G, Früh M, Reck M et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v116-v119 (2010).
11. Soria JC, Mauguen A, Reck M et al. Meta-ana lysis of randomized Phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 21(Suppl. 8) (2010) (Abstract 437P).
12. Reck M, Barlesi F, Crinò L et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann. Oncol. 23(5), 1111-1120 (2011).
13. Mok T, Gorbunova V, Juhasz E et al. Biomarker ana lysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-Gemcitabine (CG) or Carboplatin-Paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC). Presented at: 16th European Multidisciplinary Cancer Congress. Stockolm, Sweden, 23-27 September 2011.
14. Hilbe W, Manegold C, Pircher A. Targeting angiogenesis in lung cancer - pitfalls in drug development. Transl. Lung Cancer Res. doi:10.3978/j.issn.2218- 6751.2012.01.01 (2012) (Epub ahead of print).
15. Novello S, Ramlau R, Gorbunova VA et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): final results of a multinational placebo-controlled Phase III trial (EFC10261-VITAL). Presented at: 14th World Conference of Lung Cancer. Amsterdam, The Netherlands, 4-7 July 2011.
16. Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68(12), 4774-4782 (2008).
17. Garassino MC, Marabese M, Rusconi P et al. Different types of K-RAS mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann. Oncol. 22(1), 235-237 (2011).
18. Ihle NT, Byers LA, Kim ES et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst. 104(3), 228-239 (2012).
19. Paik PK, Arcila ME, Fara M et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 29(15), 2046-2051 (2011).
20. ClinicalTrials.gov. An Investigational Drug, PF-02341066 is Being Studied Versus Standard of Care in Patients with Advanced Non-Small Cell Lung Cancer with a Specific Gene Profile Involving the Anaplastic Lymphoma Kinase (ALK) Gene. http://clinicaltrials.gov/ct2/results?term=NCT00932893 (Accessed 15 March 2012)
21. ClinicalTrials.gov. A Clinical Trial Testing the Efficacy of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin or Carboplatin in Patients with ALK Positive Non Squamous Cancer of the Lung. http:// clinicaltrials.gov/ct2/results?term=NCT01154140 (Accessed 15 March 2012)
22. ClinicalTrials.gov. LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer. http://clinicaltrials.gov/ct2/results?term=NCT00805194 (Accessed 15 March 2012)
23. ClinicalTrials.gov. Lume Lung 2: BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC. http://clinicaltrials. gov/ct2/results?term=NCT00806819 (Accessed 15 March 2012)
24. ClinicalTrials.gov. Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients. http://clinicaltrials.gov/ct2/results?term=NCT00890825 (Accessed 15 March 2012)
25. ClinicalTrials.gov. A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations. http://clinicaltrials.gov/ct2/results?term=NCT01336634 (Accessed 15 March 2012)